Clinical trialNCT06834282RecruitingPhase 1Interventional

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

SponsorCERo Therapeutics Holdings, Inc.Enrollment18AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a ﬁrst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efﬁcacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
Brian Jonas, MD
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, United States
Michael Maris, MD
Recruiting
Sarah Cannon Research Insitute
Nashville, Tennessee, United States
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Abhishek Maiti, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CER-1236Cyclophosphamide →Fludarabine →Mesna →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Apr 2025
Primary completion: 31 Dec 2026
Completion: 31 Dec 2029
Last update posted: 21 Aug 2026
Registered enrollment: 18
Registry id: NCT06834282

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.